Myeloid Neoplasm Clinical Trial
Official title:
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).
Primary Objective - Determine the composite complete remission (CR) and complete remission with incomplete peripheral blood recovery (CRi) rates, safety and tolerability in patients under 22 years of age with SMN treated with one or two courses of CPX-351 before HSCT. Secondary Objectives - Describe the toxicity profile of patients with SMN treated with one or two courses of CPX-351. - Describe the biologic correlates of response in patients with SMN after one or two courses of CPX-351. - Estimate the 3-year overall survival of patients who received one or two courses of CPX-351 followed by HSCT. Participants who meet the inclusion criteria and consent will receive up to 2 cycles of CPX-351 for remission induction, and then will proceed to allogeneic HSCT or other therapies as per institutional practice. If a patient attains remission and has negative MRD after the first course of CPX-351, and HSCT can occur within 4 weeks from the evaluation date of the first course, the patient can proceed to HSCT without receiving the second course of CPX-351. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02756572 -
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
|
Phase 2 | |
| Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT01817075 -
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
|
Phase 3 | |
| Terminated |
NCT04196010 -
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
|
Phase 1 | |
| Completed |
NCT00866918 -
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
|
Phase 3 | |
| Recruiting |
NCT04195945 -
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
|
Phase 2 | |
| Recruiting |
NCT05074316 -
The Myeloid Neoplasms Biology and Outcome Project
|
||
| Active, not recruiting |
NCT01371981 -
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
Phase 3 | |
| Recruiting |
NCT04981821 -
A Randomized Trial of a Mobile Health Exercise Intervention for Older Adults With Myeloid Neoplasms
|
N/A | |
| Suspended |
NCT04797767 -
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
|
Phase 1 | |
| Active, not recruiting |
NCT03862157 -
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Completed |
NCT03012672 -
Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
|
Phase 2 | |
| Terminated |
NCT04526288 -
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
|
Phase 2 | |
| Completed |
NCT01307579 -
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
|
Phase 3 | |
| Recruiting |
NCT05796570 -
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
|
Phase 2 |